Pelvic Congestion Syndrome Treatment Market

Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain. The causes of pelvic congestion syndrome generally involves pelvic inflammatory disease, endometriosis, pelvic varicosities and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Prior to venogram, a pelvic ultrasound or other imaging study is performed to check any abnormalities.
Pelvic Congestion Syndrome Treatment Market contains market size and forecasts of Pelvic Congestion Syndrome Treatment in global, including the following market information:
Global Pelvic Congestion Syndrome Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pelvic Congestion Syndrome Treatment Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Pelvic Congestion Syndrome Treatment companies in 2021 (%)
The global Pelvic Congestion Syndrome Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pelvic Congestion Syndrome Treatment include Sanofi, TOLMAR, Actiza Pharmaceutical, Pfizer, Debiopharm Group, AbbVie, AstraZeneca, Novartis and Indivior, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pelvic Congestion Syndrome Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pelvic Congestion Syndrome Treatment Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pelvic Congestion Syndrome Treatment Market Segment Percentages, by Type, 2021 (%)
NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
Dihydroergotamine
Progestins
Others
Global Pelvic Congestion Syndrome Treatment Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pelvic Congestion Syndrome Treatment Market Segment Percentages, by Application, 2021 (%)
Primary Pelvic Congestion Syndrome
Secondary Pelvic Congestion Syndrome
Global Pelvic Congestion Syndrome Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pelvic Congestion Syndrome Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pelvic Congestion Syndrome Treatment revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pelvic Congestion Syndrome Treatment revenues share in global market, 2021 (%)
Key companies Pelvic Congestion Syndrome Treatment sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Pelvic Congestion Syndrome Treatment sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
TOLMAR
Actiza Pharmaceutical
Pfizer
Debiopharm Group
AbbVie
AstraZeneca
Novartis
Indivior
Johnson and Johnson
Fresenius Kabi
TerSera Therapeutics
Takeda
Ferring